Inactive Instrument

Clarus Therapeutics Holdings, Inc.

CRXT

US18271L1070

CLARUS THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)

August 09, 2022 at 10:26 pm

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 8, 2022, Joseph Hernandez informed Clarus Therapeutics Holdings, Inc., or Clarus, of his intention to resign as a member of its board of directors, or the Board, and its committees, effective immediately. Mr. Hernandez's decision to resign from the Board did not result from any disagreement with Clarus on any matter relating to its operations, policies, or practices.

--------------------------------------------------------------------------------

Latest news about Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. Went Out of Business	28/02/23	CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.	09/02/23	CI
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.	17/01/23	CI
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.	29/12/22	CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.	22/12/22	CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.	21/12/22	CI
Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.	01/12/22	CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer	31/10/22	CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022	31/10/22	CI
Clarus Therapeutics Holdings, Inc. Announces Executive Changes	31/10/22	CI
Motion for Asset Sale Approved for Clarus Therapeutics Holdings, Inc.	26/10/22	CI
Bidding Procedure Approved for Clarus Therapeutics Holdings, Inc.	22/09/22	CI
Motion for Joint Administration Approved for Clarus Therapeutics Holdings, Inc.	07/09/22	CI
Health Care Up on Deal Activity -- Health Care Roundup	06/09/22	DJ
Motion for Asset Sale Filed by Clarus Therapeutics Holdings, Inc.	05/09/22	CI
Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc.	05/09/22	CI
Clarus Therapeutics Holdings, Inc. Filed for Bankruptcy	05/09/22	CI
Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from S&P TMI Index	02/09/22	CI
Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from NASDAQ Composite Index	30/08/22	CI
Top Premarket Decliners	29/08/22	MT
North American Morning Briefing : Stock Futures -2-	23/08/22	DJ
Needham & Co Downgrades Clarus Therapeutics to Hold From Buy	22/08/22	MT
Maxim Downgrades Clarus Therapeutics Holdings to Hold From Buy	22/08/22	MT
Sector Update: Health Care Stocks Cross Friday Finish Line Slightly Higher	19/08/22	MT
Sector Update: Health Care Stocks a Rare Positive in Friday Trading	19/08/22	MT

Chart Clarus Therapeutics Holdings, Inc.

Duration

Period

Chart Clarus Therapeutics Holdings, Inc.

More charts

Company Profile

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company. The Company is engaged in the development of androgen-based medicines. The Company is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. It also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company's subsidiary is Clarus Therapeutics, Inc.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+42.99%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-6.24%	356B
MERCK & CO., INC.	+18.50%	326B
ABBVIE INC.	+6.37%	286B
ASTRAZENECA PLC	+18.58%	246B
ROCHE HOLDING AG	-3.15%	213B
NOVARTIS AG	+11.21%	213B
PFIZER, INC.	+2.28%	167B

Other Pharmaceuticals